Supernus Pharm (SUPN) Misses Q1 Loss Views

Supernus Pharm (NASDAQ: SUPN) reported Q1 EPS of ($1.51), $0.02 worse than the analyst estimate of ($1.49).

After adjustment for a 4-for-1 reverse split, the first-quarter loss was $6.05 per share.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Lumentum shares rise on analyst upgrades, AI demand outlook
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained